-
Je něco špatně v tomto záznamu ?
The relationship between renal cell carcinoma and nuclear retinoid/rexinoid receptors
V. Lenko, L. Bialesova, D. Macejova, P. Bujdak, J. Breza, J. Brtko
Jazyk angličtina Země Česko
Typ dokumentu časopisecké články, práce podpořená grantem, přehledy
NLK
Directory of Open Access Journals
od 2001
Free Medical Journals
od 1998
Medline Complete (EBSCOhost)
od 2007-06-01
ROAD: Directory of Open Access Scholarly Resources
od 2001
PubMed
24077234
DOI
10.5507/bp.2013.060
Knihovny.cz E-zdroje
- MeSH
- karcinom z renálních buněk etiologie MeSH
- lidé MeSH
- nádory ledvin etiologie MeSH
- receptory cytoplazmatické a nukleární fyziologie MeSH
- receptory kyseliny retinové fyziologie MeSH
- retinoidní X receptory fyziologie MeSH
- rizikové faktory MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
BACKGROUND: Renal cell carcinoma (RCC) is a urologic malignancy with a steady rise in incidence and high mortality rate. Between 60 to 70% of patients with renal cell carcinoma can only be cured with surgery but despite advances in early diagnostis, in around 20-30% of cases there is metastasis. For these patients, chemotherapy and radiotherapy are ineffective and hence the prognosis is poor. Retinoids are biologically active compounds of either natural or synthetic origin that are involved in complex physiological and developmental processes in many tissues including cell proliferation and activation of tumour suppression genes. This article reviews the role of retinoids and their cognate nuclear retinoid/rexinoid receptors in relation to renal cell carcinoma. METHODS: A literature search using ScienceDirect and Medline with a focus on the relationship between renal cell carcinoma and nuclear retinoid/rexinoid receptors. RESULTS: Use of retinoids/rexinoids in the treatment of locally advanced and metastatic RCC significantly prolongs median time of tumour progression and overall survival of patients. Combination therapy with other preparations has greater efficacy than treatment with retinoids alone. Patient survival can be predicted on the basis of the expression of different all-trans retinoic acid receptor (RAR) and 9-cis retinoic acid receptor (RXR) subtypes. CONCLUSIONS: Since nuclear retinoid receptors play a crucial role as ligand-activated, DNA binding, trans-acting, transcription-modulating proteins involved in a general molecular mechanism responsible for transcriptional responses in target genes, retinoids might be an alternative approach for the treatment of renal cell carcinoma.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc15026684
- 003
- CZ-PrNML
- 005
- 20150818085845.0
- 007
- ta
- 008
- 150811s2013 xr a f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.5507/bp.2013.060 $2 doi
- 035 __
- $a (PubMed)24077234
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Lenko, Vladimir $u Laboratory of Molecular Endocrinology, Institute of Experimental Endocrinology, Slovak Academy of Sciences, Bratislava, Slovak Republic; Department of Urology, University Hospital Bratislava, St. Cyril and Method Hospital, Bratislava, Slovak Republic $7 _AN083796
- 245 14
- $a The relationship between renal cell carcinoma and nuclear retinoid/rexinoid receptors / $c V. Lenko, L. Bialesova, D. Macejova, P. Bujdak, J. Breza, J. Brtko
- 520 9_
- $a BACKGROUND: Renal cell carcinoma (RCC) is a urologic malignancy with a steady rise in incidence and high mortality rate. Between 60 to 70% of patients with renal cell carcinoma can only be cured with surgery but despite advances in early diagnostis, in around 20-30% of cases there is metastasis. For these patients, chemotherapy and radiotherapy are ineffective and hence the prognosis is poor. Retinoids are biologically active compounds of either natural or synthetic origin that are involved in complex physiological and developmental processes in many tissues including cell proliferation and activation of tumour suppression genes. This article reviews the role of retinoids and their cognate nuclear retinoid/rexinoid receptors in relation to renal cell carcinoma. METHODS: A literature search using ScienceDirect and Medline with a focus on the relationship between renal cell carcinoma and nuclear retinoid/rexinoid receptors. RESULTS: Use of retinoids/rexinoids in the treatment of locally advanced and metastatic RCC significantly prolongs median time of tumour progression and overall survival of patients. Combination therapy with other preparations has greater efficacy than treatment with retinoids alone. Patient survival can be predicted on the basis of the expression of different all-trans retinoic acid receptor (RAR) and 9-cis retinoic acid receptor (RXR) subtypes. CONCLUSIONS: Since nuclear retinoid receptors play a crucial role as ligand-activated, DNA binding, trans-acting, transcription-modulating proteins involved in a general molecular mechanism responsible for transcriptional responses in target genes, retinoids might be an alternative approach for the treatment of renal cell carcinoma.
- 650 _2
- $a karcinom z renálních buněk $x etiologie $7 D002292
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a nádory ledvin $x etiologie $7 D007680
- 650 _2
- $a receptory cytoplazmatické a nukleární $x fyziologie $7 D018160
- 650 _2
- $a receptory kyseliny retinové $x fyziologie $7 D018168
- 650 _2
- $a retinoidní X receptory $x fyziologie $7 D047488
- 650 _2
- $a rizikové faktory $7 D012307
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Bialešová, Lucia $7 _AN083797 $u Laboratory of Molecular Endocrinology, Institute of Experimental Endocrinology, Slovak Academy of Sciences, Bratislava, Slovak Republic
- 700 1_
- $a Macejová, Dana $7 xx0061612 $u Laboratory of Molecular Endocrinology, Institute of Experimental Endocrinology, Slovak Academy of Sciences, Bratislava, Slovak Republic
- 700 1_
- $a Bujdák, Peter $7 xx0126325 $u Department of Urology, Faculty of Medicine, Slovak Medical University, Bratislava, Slovak Republic
- 700 1_
- $a Breza, Ján, $7 _BN004042 $u Department of Urology, Faculty of Medicine, Slovak Medical University, Bratislava, Slovak Republic
- 700 1_
- $a Brtko, Július $7 xx0121874 $u Laboratory of Molecular Endocrinology, Institute of Experimental Endocrinology, Slovak Academy of Sciences, Bratislava, Slovak Republic
- 773 0_
- $w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacký, Olomouc, Czech Republic $x 1213-8118 $g Roč. 157, č. 4 (2013), s. 316-324
- 910 __
- $a ABA008 $b A 1502 $c 958 $y 4 $z 0
- 990 __
- $a 20150811 $b ABA008
- 991 __
- $a 20150812132412 $b ABA008
- 999 __
- $a ok $b bmc $g 1087894 $s 909720
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2013 $b 157 $c 4 $d 316-324 $e 20130911 $i 1213-8118 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606
- LZP __
- $b NLK118 $a Pubmed-20150811